Single dose of gruticibart to prevent blood clot complications
Part of Heart & circulation clinical trials.
This trial tests if a single dose of a drug called gruticibart can help prevent blood clots caused by a central line (a special IV tube) inserted for cancer treatment. It may be an option for adults starting therapy that requires this type of IV access.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You are scheduled to have a central line placed as part of your cancer treatment
- You are able to delay the start of your cancer therapy by 1 to 2 days to receive the study drug
- Your overall health is good enough (ECOG score 0, 1, or 2)
- Your platelet count is above 50,000 per microliter of blood
- You are not currently taking blood thinners or have a known bleeding disorder
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a full dose of rivaroxaban (a blood thinner) works better than a lower preventive dose for treating a superficial vein clot in the leg. It aims to find the safest and most effective way to stop the clot from getting worse or causing a more serious clot.
This trial tests whether starting enoxaparin (a blood-thinner) within 24 hours after placing a specific type of central line can prevent dangerous clots. It may help reduce clot risk in people whose line is placed in the neck or thigh vein, while also tracking bleeding side effects.
This study tests two experimental drugs, REGN7508 and REGN9933, to see if they can safely prevent blood clots in the arm or chest in people who need a PICC line. If you are getting a PICC for treatments like chemotherapy or antibiotics, you may be able to join.
This trial tests whether rivaroxaban, a blood thinner pill, can help prevent dangerous blood clots in people with certain genitourinary cancers who are starting cancer treatment. It may lower clot risk, but it also has bleeding-risk tradeoffs that the study will monitor closely.
This trial tests a new anticoagulant medication to treat and prevent blood clots in patients with active cancer. You may qualify if you have a recent clot in your leg or lungs and are already taking a blood thinner.
This Phase 3 study tests whether the medicine rivaroxaban can prevent dangerous blood clots in people with cancer who have a central venous catheter placed recently. It may help reduce clot risk while your catheter is in place, but you must meet safety and bleeding-risk criteria.
Hear when a new Thrombosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.